文献速递浆细胞疾病

Venetoclax联合达雷妥尤单抗及地塞米松±硼替佐米治疗复发难治多发性骨髓瘤的I期研究

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
PubMed 文献 · J Clin Oncol · 2021-08-13

这项I期研究评估了VenDd方案(t(11;14) RRMM)和VenDVd方案(细胞遗传学未选择RRMM)的剂量扩展、安全性和总缓解率。18个月无进展生存率分别为90.5%和66.7%。两方案产生高比例深度持久缓解,支持进一步评估Venetoclax联合达雷妥尤单抗方案。

要点

  • VenDd在t(11;14) RRMM中总缓解率96%且均≥VGPR。
  • VenDVd在细胞遗传学未选择RRMM中总缓解率92%。
  • 常见不良事件为腹泻和恶心,≥3级不良事件发生率分别为88%和71%。

核心结论

  • VenDd和VenDVd在复发难治多发性骨髓瘤中产生高比例深度持久缓解,支持继续评估Venetoclax联合达雷妥尤单抗方案,尤其对t(11;14)患者。

研究设计与样本

  • I期研究(NCT03314181),评估VenDd用于t(11;14) RRMM和VenDVd用于细胞遗传学未选择RRMM。
  • 主要目标包括扩展期给药、安全性和总缓解率;次要目标包括进一步安全性分析、无进展生存、缓解持续时间、至进展时间和微小残留病阴性。

主要发现

  • 第1部分发生1例剂量限制性毒性(3级发热性中性粒细胞减少,800 mg VenDd)。
  • VenDd和VenDVd常见不良事件包括腹泻(63%和54%)和恶心(50%和50%);≥3级不良事件分别见于88%和71%的患者。
  • 第2部分发生1例治疗中出现死亡(脓毒症),背景为疾病进展;中位随访20.9个月(第1部分)和20.4个月(第2部分)期间无其他感染相关死亡。
  • VenDd总缓解率96%(全部≥VGPR);VenDVd总缓解率92%(79%≥VGPR)。
  • 18个月无进展生存率:VenDd为90.5%(95%CI 67.0至97.5),VenDVd为66.7%(95%CI 42.5至82.5)。

临床怎么用

  • 对于伴t(11;14)的RRMM患者,VenDd方案可考虑作为高缓解率的选择,但需注意监测腹泻、恶心及≥3级不良事件。
  • 对于细胞遗传学未选择的RRMM患者,VenDVd方案也可获得高缓解率,但18个月PFS率低于VenDd组。

局限性

  • 随访时间有限(中位约20个月),长期生存获益尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may be potentiated through combination with agents including bortezomib, dexamethasone, and daratumumab. METHODS: This phase I study (NCT03314181) evaluated venetoclax with daratumumab and dexamethasone (VenDd) in patients with t(11;14) RRMM and VenDd with bortezomib (VenDVd) in cytogenetically unselected patients with RRMM. Primary objectives included expansion-phase dosing, safety, and overall response rate. Secondary objectives included further safety analysis, progression-free survival, duration of response, time to progression, and minimal residual disease negativity. RESULTS: Forty-eight patients were enrolled, 24 each in parts 1 (VenDd) and 2 (VenDVd). There was one dose-limiting toxicity in part 1 (grade 3 febrile neutropenia, 800 mg VenDd). Common adverse events with VenDd and VenDVd included diarrhea (63% and 54%) and nausea (50% and 50%); grade ≥ 3 adverse events were observed in 88% in the VenDd group and 71% in the VenDVd group. One treatment-emergent death occurred in part 2 (sepsis) in the context of progressive disease, with no other infection-related deaths on study with medians of 20.9 and 20.4 months of follow-up in parts 1 and 2, respectively. The overall response rate was 96% with VenDd (all very good partial response or better [≥ VGPR]) and 92% with VenDVd (79% ≥ VGPR). The 18-month progression-free survival rate was 90.5% (95% CI, 67.0 to 97.5) with VenDd and 66.7% (95% CI, 42.5 to 82.5) with VenDVd. CONCLUSION: VenDd and VenDVd produced a high rate of deep and durable responses in patients with RRMM. These results support continued evaluation of venetoclax with daratumumab regimens to treat RRMM, particularly in those with t(11;14).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bahlis NJ, Baz R, Harrison SJ, et al. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). J Clin Oncol. 2021. PMID: 34388020. doi:10.1200/JCO.21.00443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。